ATS Gets $3M in Cancer Funding
Bruce V. Bigelow9/24/10
The National Cancer Institute awarded $3 million to San Diego’s Advanced Targeting Systems, a company that develops and provides products for neuroscience researchers, and has developed technology for targeting specific types of cells. In 1997, for example, ATS developed SP-SAP, a reagent that eliminates specific pain transmission neurons that propagate chronic pain signals. In a statement released today, ATS says it plans to use the institute funding to advance SP-SAP for the next two years to initiate clinical trials for treating cancer pain.













Pingback: ATS Gets $3M in Cancer Funding | Xconomy « Health Academy